TuHURA Biosciences, Inc. (NASDAQ:HURA) reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor (DOR) technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility following eligibility to file a shelf registration statement on Form S-3.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24219) on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.